The Australia Custom Antibody Market was valued at $2.2 Million in 2024 and projected to reach to $3.4 Million by 2029, representing a compound annual growth rate of 8.7%. Australia's custom antibody market is poised for sustained expansion through 2029, driven by escalating investments in biotechnology research and the country's growing reputation as a life sciences innovation center.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
Australia's custom antibody market is valued at $2.2 million in 2024, with strong growth momentum driven by increased R&D spending in the biotechnology sector across major research institutions and pharmaceutical companies.
The market is projected to reach $3.4 million by 2029, representing a robust 8.7% CAGR. This growth outpaces many developed markets, reflecting Australia's commitment to advancing therapeutic innovation and personalized medicine.
Australia serves as a critical hub within the Asia Pacific region for custom antibody development, leveraging its advanced research infrastructure, skilled workforce, and strategic partnerships with global biotech leaders.
Rising demand for personalized therapeutic solutions and monoclonal antibody-based treatments is driving market expansion, supported by increased government funding for life sciences research and development initiatives.
| COMPANY | USE CASE DESCRIPTION | BENEFITS |
|---|---|---|
|
|
Provides custom antibody development and production services, including monoclonal, polyclonal, and recombinant antibody generation. Its services cover antigen design, antibody screening, purification, and characterization for research and diagnostic applications. | Supports the development of application-specific antibodies with defined target specificity and performance, helping pharmaceutical companies, biotechnology firms, and academic researchers accelerate target validation and assay development. |
|
|
Offers custom antibody production and engineering services through its antibody development capabilities, including GeneArt high-throughput antibody expression, gene synthesis, cloning, transient expression, purification, and quality control. | Enables researchers to obtain custom antibodies for research and development workflows, supporting faster antibody production, consistent quality, and applications in biologics development, protein analysis, and diagnostic research. |
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
| Report Metric | Details |
|---|---|
| Base Year | 2024 |
| Fastest Growing Segment | ONCOLOGY (Indication) |
| Forecast Period | 2024-2029 |
| Growth Rate | CAGR of 9.2% from 2024 to 2029 |
| Largest Segment | RESEARCH (Application) |
| Market Size Base Year (Billions) | ~USD 0.58 (2024) |
| Revenue Forecast (Billions) | ~USD 0.9 (2029) |
| Segments Covered | Service, Type, Source, Application, Indication, End User |
6 segment dimensions are covered across the global market.
Australia's custom antibody market was valued at $2.2 million in 2024 and is expected to grow to $3.4 million by 2029.
Australia's custom antibody market is growing at a compound annual growth rate (CAGR) of 8.7% from 2024 to 2029.
Growth in Australia is driven by increased biotech research investment, rising demand for immunotherapy solutions, government support for life sciences, and expansion of diagnostic applications.
Australia represents a significant segment within the Asia Pacific custom antibody market, with strong growth momentum supported by advanced research infrastructure and healthcare capabilities.
Key applications in Australia include immunotherapy development, diagnostic assays, research applications, and therapeutic antibody development for precision medicine.
The global custom antibody market is projected to reach USD 1.13 billion by 2031, up from USD 0.72 billion in 2026, reflecting a 9.5% CAGR over the forecast period. Market estimation involved four major activities to estimate the current size of the custom antibody market. Exhaustive secondary research was conducted to gather information on the market, its peer markets, and its parent market. These findings, assumptions, and sizing were then validated with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the total market size. Following this, data triangulation was used to estimate the market size of segments and subsegments.
Secondary research was used mainly to identify and collect information for the extensive, technical, market-oriented, and commercial study of the custom antibody market. The secondary sources used for this study include Antibody Society, Antibody Therapeutics, Pharmaceutical Research and Manufacturers of America (PhRMA), National Center for Biotechnology Information (NCBI), National Institutes of Health (NIH), American Medical Association (AMA), Association of Medical Laboratory Immunologists (AMLI), Central Drugs Standard Control Organisation (CDSCO), Center for Drug Evaluation and Research (CDER), Centers for Disease Control and Prevention (CDC), National Cancer Institute (NCI), European Medicines Agency (EMA), Biotechnology and Biological Sciences Research Council (BBSRC), World Health Organization (WHO), and United States Food & Drug Administration (USFDA).
Secondary sources also include corporate and regulatory filings (annual reports, SEC filings, investor presentations, and financial statements); business magazines & research journals; press releases; trade, business, and professional associations; and MarketsandMarkets Analysis. These sources were also used to obtain key information about major players, market classification, and segmentation according to industry trends, regional/country-level markets, market developments, and technology perspectives.
In-depth interviews were conducted with primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among others, to obtain and verify critical qualitative and quantitative information and to assess market prospects. Primary sources from both the supply and demand sides of the market were interviewed to gather qualitative and quantitative data. The following is a breakdown of the primary respondents:
Breakup of Primary Profiles:

To know about the assumptions considered for the study, download the pdf brochure
The global size of the custom antibody market was estimated using multiple approaches. A detailed market estimation approach was used to estimate and validate the market value and other dependent submarkets. These methods were also used extensively to estimate the size of various market subsegments. The research methodology used to estimate the market size includes the following.

After estimating the market size using the process described above, the total market was divided into several segments and subsegments. To finish the overall market analysis and obtain precise statistics for all segments and subsegments, data triangulation and market breakdown methods were used where applicable. The data were triangulated by examining various factors and trends from both the demand and supply sides.
Custom antibody services include the production of antibodies from a wide variety of host species, depending on the desired outcome of the research study. These services range from antigen preparation, immunization, hybridoma production, and antibody characterization to production, purification, and labeling. The report includes the market size and forecast for custom antibody development, production, purification, and labeling services.
With the provided market data, MarketsandMarkets offers customization to meet the company’s specific needs. The following options are available for the report:
Full forecast, segment splits, and company analysis for all Custom Antibody Market.
Customize this report to your needs
Get 10% FREE Customization
Customize This Report